Gsa Capital Partners LLP Capricor Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$4.63 - $7.09 $126,537 - $193,769	27,330 New	27,330 $130,000
Q4 2023 Feb 16, 2024	SELL	$2.71 - $5.08 $29,362 - $55,041	-10,835 Reduced 24.73%	32,970 $161,000
Q3 2023 Nov 15, 2023	BUY	$3.42 - $7.85 $88,629 - $203,432	25,915 Added 144.86%	43,805 $149,000
Q2 2023 Aug 14, 2023	BUY	$3.76 - $5.05 $67,266 - $90,344	17,890 New	17,890 $85,000
Q4 2021 Feb 14, 2022	SELL	$2.89 - $4.16 $279,266 - $401,989	-96,632 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$3.8 - $5.23 $59,781 - $82,278	-15,732 Reduced 14.0%	96,632 $388,000
Q2 2021 Aug 05, 2021	BUY	$3.16 - $5.72 $309,815 - $560,805	98,043 Added 684.61%	112,364 $576,000
Q1 2021 May 10, 2021	SELL	$3.63 - $7.93 $235,115 - $513,626	-64,770 Reduced 81.89%	14,321 $67,000
Q4 2020 Feb 03, 2021	BUY	$3.43 - $5.23 $271,282 - $413,645	79,091 New	79,091 $271,000

8.13M

1.78M

1.4M

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $450M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.